O-GYN-MD-126 Primary Efficacy and Safety Results from Two Double-Blind, Randomized, Placebo-Controlled Studies Of Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, in Women With Endometriosis-Associated Pain

Sukhbir S. Singh, H. Taylor, Linda C. Giudice, Bruce A. Lessey, Maurício Simões Abrão, Jan Kotarski, W. Rachel Duan, Brittany Schwefel, J. Graham Thomas, Kristof Chwalisż
In: Journal of Obstetrics and Gynaecology Canada · 2017 · vol. 39(5) , pp. 401 · doi:10.1016/j.jogc.2017.03.067 · W2608055913
article OA: closed CC0 ⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study evaluated the efficacy and safety of elagolix, an oral GnRH antagonist, for treating endometriosis-associated pain in women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK